Drug Discovery

-Real-time PCR
-Assy development
-Target Validation/identification
-Bioinformatics
-Therapeutics
-Compound Screening
-Lead Optimisation
-Genomics/Proteomics

The pharmaceutical industry is driven by the productivity of its R&D. Despite its success, the environment in which the pharmaceutical industry operates is becoming more competitive and the R&D process to bring a drug successfully to market remains challenging.

Drug development is a risky and expensive process and involves combining scientific excellence with a thorough understanding of the business environment. Industry leaders responsible for the world’s most successful pharmaceutical facilities will bring insight and examine the best strategies to ensure pharmaceutical companies can bring new drugs to market quicker and more efficiently.

Contributors

Expert’s forum: Advances in drug discovery
GE Healthcare’s Kevin Daish and Joseph P. Brown of LifeSpan BioSciences talk latest developments.
More >>

When two heads are better than one
According to PA Consulting’s Jan Malek, R&D president isn’t one job – it’s two. Maybe it’s time to create a new position...
More >>

Closing the functionality gap with off-the-shelf pharmaceutical LIMS
The new buzzword in the pharmaceutical industry, COTS, refers to commercial-off-the-shelf and it is being used frequently in reference to laboratory software.
More >>

LIMS: An inside perspective
Karl Yorgey works with the GPCD in the pre-clinical organization for Johnson & Johnson, supporting all of the GLP applications within preclinical.
More >>

LIMS: an executive perspective
NGP talks with Dave Champagne, Vice President and General Manager of Thermo’s Informatics Business, about the future of laboratory information management systems.
More >>

Technical study: battle at the gates – combating mutant kinases
Molecular therapeutics that target proteins kinases represent a major advance in the treatment of disease, particularly cancer.
More >>

Technical study: robust calcium mobilization
Robust calcium mobilization by a broad range of overexpressed GPCRs in cell lines containing endogenous promiscuous G proteins.
More >>

Technical study
Universal HTRF lipid kinase and STK assays.
More >>

Targeting treatment
Personalized medicine: offering the promise of individualized therapy by incorporating molecular analyses.
More >>

Making the most of your knowledge
Optimizing scientific information management in pharmaceutical product development.
More >>

Work better, faster, smarter
How to accelerate R&D.
More >>

The right chemistry
Dr Jim Summers talks about a revolution in pharmaceutical research: combinatorial chemistry.
More >>

The hard cell: Genomics and the future of drug discovery
By Dr Christopher Austin, Senior Advisor to the Director for Translational Research and Director of the National Institutes of Health (NIH) Chemical Genomics Center, National Human Genome Research Institute.
More >>

Gene genies
Jay Flatley, Illumina, and Doug Amorese, Agilent, go head-to-head on one of pharma?s hottest topics.
More >>

A neutral forum to enhance world health
The DIA is critical to the advancement of drug discovery. Why? DIA President Theresa Musser tells us more.
More >>

ChemiScreen novel GPCR stable cell lines for calcium mobilization assay platforms
Historically, successful drugs have been discovered without an understanding of the molecular details of their mechanism of action
More >>

RNAi goes genomic: target identification and validation with siRNAs
Recent genomics and proteomics initiatives, including microarray-based transcriptional profiling and analyses of protein interaction networks, have led to the identification of large numbers of potential drug targets.
More >>

Innovative technologies from QIAGEN
QIAGEN continually expands and develops the range of products and services available to incorporate newly developing technologies and to facilitate research and discovery in the fast-moving life sciences area.
More >>

Chemical reaction
Medicinal chemistry continues to be confronted with new opportunities to explore and refine the predictive potential of drug design.
More >>

Target acquired
Ambion?s David Dorris and Qiagen?s Walter Tian on how to exploit the benefits of RNAi.
More >>

Banking on IT
New technology needs new rules to be most effective. Brock Reeve talks biobanks.
More >>

Making the most of your knowledge
Optimizing scientific information management in pharmaceutical product development.
More >>

Size matters
How the tiny world of nanotechnology is having a big impact on the pharma industry.
More >>

Research focus: gene expression profiling
Tissue, disease and species specificity testing of potential candidate biomarkers using expression profiling.
More >>

Molecular imaging
Kirtland Poss, Co-founder, President & CEO of VisEn, gives us some background into this imaging technology and explains how pioneering new techniques are likely to impact drug development today and in the future.
More >>

Biomarkers: yesterday’s tomorrow today
T-Gen?s David Evans tells NGP what the future holds for patients, biomarkers and the industry, revealing that from the beginnings of the field to the present day and beyond, a world of opportunity lies ahead.
More >>

Analyse this
Peter Nelson, Lab Manager at Micron Technologies, met with NGP for a quick Q&A.
More >>

Profiling the profilers
In the last edition of NGP, Jeffrey Till gave us a brief insight into the role of kinase profiling in drug development. We caught up with Jeff to find out more.
More >>

Optimizing efficiency with electronic regulatory submissions
A large generic pharmaceutical company has research, development, manufacturing and distribution operations worldwide including North America, South America, Europe, Asia and Australia.
More >>

Standard issue
NGP speaks with Professor Antony N Davies, Senior Marketing Manager, Waters Informatics about how the use of standards is a powerful enabling technology for moving information cleanly and in a compliant manner between applications.
More >>

Optical Mapping
Colin Dykes, Chief Scientific Officer and Executive Vice-President of Corporate Development, OpGen, gives us the lowdown on the importance of optical mapping in healthcare and what’s next for the technology.
More >>

The big squeeze
According to Nick Hughes at the PA Consulting Group, the ability of the pharma industry to generate much-needed cash for new drug discovery is being eroded by the coincidence of multiple events.
More >>

A voice for drug development
Jeff Bizzaro, Chairman of Bioinformatics.Org, speaks to NGP about the growing interest and emphasis on openness and transparency of information and practices in the industry and what changes are occurring.
More >>

A global call for informatics practice
Advancements in IT promise dramatic leaps forward in our ability to discover, develop and deliver new medical diagnostics and therapeutics.
More >>

First steps
In drug development, incorporating pharmacogenetic testing into early phase clinical trials could reduce the likelihood of unexpected adverse reactions in later trials, by allowing drug safety to be assessed in a variety of relevant genetic backgrounds.
More >>

Electron tomography
The development of a unique protein tomography technology, for the analysis of protein complexes in their biological context, could prove critical in improving the success rate of modern drug development.
More >>

Bridging the gap
A large informational gap remains between a gene?s sequence and its biological function, and an even greater gap between the gene?s function and its complicated interactions with other genes.
More >>

Metabolic profiling
Unique, patent-pending tracer technology measures metabolic pathway flux to gain unique insight into cell function.
More >>

The role of kinase profiling in drug development
Kinase profiling allows researchers to screen inhibitors against a large panel of kinases
More >>

A problem shared?
It has never been more vital that the industry carefully assess how to utilize internal resources.
More >>

Use it or lose it! ? keeping control of your data
Drug discovery R&D places considerable and unique demands on the data generated
More >>

Speeding things up
Enabling data integration across the research organization is an effective way of boosting productivity for a pharmaceutical organization. Innovating affordably without sacrificing quality is a difficult balance to muster.
More >>

Reaching that Eureka! Moment
An essential ingredient in any successful research and development program is information.
More >>

From data management to knowledge management
The last 10 years has seen enormous advances in computing power but it has also seen an even greater rise in the burden of work placed on the shoulders of our R&D staff.
More >>

RNAi libraries
High throughput transfection with Nucleofector technology.
More >>

Sidmap - Drug Discovery & Development Roundtable: Analyze this!
Five industry experts, all sharing one ultimate goal, discuss the real differences that a new generation of unique tools can and are making in drug discovery and development today.
More >>

Cell mates
Dr Ellen Feigal of TGen explains why the sequencing of the human genome is so revolutionary in understanding, diagnosing and treating cancer.
More >>

The fount of knowledge?
A novel way of beating the brain drain
More >>

Crisis? What crisis?
A fresh diagnosis of big pharma?s R&D productivity crunch
More >>

Getting the big picture on pharma
NGP speaks exclusively to Steve Arlington, Global Industry Leader Life Sciences/Pharma IBM Business Consulting Services.
More >>

Faster, safer, better
The FDA works to speed the advent of new, more effective personalized medicines while monitoring the risk of existing pharmaceuticals.
More >>

Biomarker discovery and development using gene expression profiling
The discovery and application of biomarkers plays a major role in drug development by providing key indicators of an individual?s disease status and a compound?s activity, efficacy or toxicity.
More >>

Impacting healthcare
Looking at RNA interference therapeutics
More >>

RNAi ? novel strategies that facilitate high-throughput screening
A powerful technology for assessing gene function
More >>

A new era of tissue-omics
Analysis of disease tissues is an efficient approach to identify new disease-associated genes and proteins
More >>

Come together
Dennis Harney, PhD, Edward Hejlek and Timothy McBride take a closer look at Collaborative research and the CREATE Act
More >>

Challenges in next generation pharmacology need world-class science tools
Looking at the explosion of data and accompanying explosion in computing needs in the pharmaceutical industry
More >>

Faster innovation cycles through microfluidics technology
Kevin Hrusovsky, President and CEO, Caliper Life Sciences looks at a leading edge solution capable of addressing serious challenges in the drug discovery industry
More >>

From antigen sequence to antibody in record time
Two innovative technologies combined for the high-throughput generation of antigens and antibodies
More >>

The new role of SFC in pharmaceutical discovery and development
By Dr. Les Dolak, LADChrom Technologies
More >>

Urgently required: anti-CD33 antibodies
This article looks at how cancer research is accelerated through the rapid production of recombinant antibodies to CD33.
More >>

The antibody library
Achim Knappik, PhD, Senior Director R&D, of Antibodies By Design speaks to NGP about the benefits of new antibody design technologies.
More >>

Delivering improvement
Finding solutions for customers ? from clinical trials packaging through to the consumer ? is not the traditional role of a manufacturer of healthcare packaging systems.
More >>

The importance of leachables and extractables testing for a successful product launch
The FDA Guidance for Industry, Container Closure Systems for Packaging Human Drugs and Biologics addresses the review and evaluation of packaging requirements.
More >>

A reagent system for gene expression profiling
A look at a proprietary cell-based signal amplification system for gene expression profiling.
More >>

Using diseases to find cures
?Trying to obtain more information from diseased tissues will be an important step to improving the efficacy of drug development?
More >>

A chance for pharmaceutical drug development
Frank Gebhardt, Ph.D., Head of Target Validation, atugen AG, Berlin, Germany, looks further at the development and potential for RNAi.
More >>

Case study: The right chemistry
On 20 October, Charles River Laboratories International, Inc. and Inveresk Research Group, Inc. officially merged under the Charles River Laboratories name
More >>

How can we accelerate drug development?
By Hartmut Juhl MD PhD, CEO of Indivumed GmbH, Center for Cancer Research at the Israelitisches Krankenhaus, Hamburg, Germany
More >>

Walking the critical path
?Collaboration is essential for success. We need to collectively embark on an aggressive, well-coordinated research to create a new generation of performance standards and predictive tools for drug development.?
More >>

Priorities in R&D: Pushing things forward
NPG speaks exclusively to Dr Robert Ruffolo, Jr.,Ph.D. President at Wyeth Research and Stephen Lederer, Senior Director at Pfizer about their current priorities in R&D including current focus areas, drivers and the role of new centres of excellence.
More >>

Ship of dreams
The National Human Genome Research Institute (NHGRI) was established in 1989 with the primary mission to lead the National Institutes of Health (NIH) contribution to the Human Genome Project (HGP).
More >>

Might a bell toll for US Pharma?
According to Juan Enríquez, bestselling author, businessman and academic, US global pharmaceutical dominance may be quite a bit more fragile that is apparent at first glance.
More >>

NIH Roadmap; Heading in the right direction
Since its launch last year, the National Institutes of Health Roadmap has taken crucial steps towards accelerating medical discovery in the US.
More >>

Technology chips in to help science
By Neil Davey (NGP)
Microchips have revolutionised the electronics industry. Now they are set to do the same to chemical laboratories.
More >>

On side
Why ACRO is supporting and assisting the Critical Path initiative.
More >>

Size isn?t everything
NGP talks with Scott Mize, President of Foresight Institute, about the vast implications that the tiny world of nanotechnology could have for life sciences.
More >>